Tyrosine Kinase Inhibitors In Metastatic Non Small Cell Lung Cancer

Istituto Clinico Humanitas

Status: Unknown

Conditions: Non Small Cell Lung Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT01163058

ONC/OSS-01/2010

Details and patient eligibility

About

Aim of the present retrospective study is to evaluate molecular factors of primary resistance to tyrosine kinase inhibitors in metastatic non small cell lung cancer (NSCLC) patients. The investigators assess first, the incidence of epidermal growth factor receptor (EGFR) and Kirsten ras sarcoma viral oncogene homolog (KRAS) mutations, SOS and hepatocyte growth factor (HGF) expression, anaplastic lymphoma kinase (ALK) translocation and expression and, secondly, the investigators correlate molecular markers with clinical features and outcome in terms of response rate, progression free survival and overall survival.

Full description

Non small cell lung cancer patients.

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed diagnosis of NSCLC (non small cell lung cancer) with available tumor tissue for mutational analysis
• Metastatic disease treated with gefitinib or erlotinib
• Presence of at least one measurable lesion according to RECIST criteria

Exclusion criteria

• No tumor tissue available
• No clinical data available